On behalf of the Federal Council, the Swiss National Science Foundation (SNSF) launched the National Research Program "Covid-19" (NRP 78) at the end of April 2020. Of the 28 new COVID-19 research projects that are being funded, two are led by DKF research group leaders:

> «Canakinumab in Patients with COVID-19 and Type 2 Diabetes: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial»

Principal Investigators

• Prof. Marc Donath (Endokrinologie, Diabetologie & Metabolismus/USB)
• Prof. Manuel Battegay (Infektiologie&Spitalhygiene)
• Prof. Philip Schütz (Allgemeine Innere und Notfallmedizin/ KSA)

> «Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of critical SARS-CoV-2 infection in hospitalized patients with COVID-19: a randomized, parallel-group, openlabel, multi-center exploratory trial»

Principal Investigator

• PD Dr. Michael Osthoff (Innere Medizin/USB).